Enjoy complimentary customisation on priority with our Enterprise License!
The organs of the abdomen are situated in a sac-like structure called the peritoneum. Generally, the amount of fluid in the peritoneal cavity is very less. This can vary by 20 ml or less than an ounce in women depending on the menstrual cycle. Ascites can be defined as an accumulation of fluid in the peritoneal cavity. It has been observed a variety of diseases can cause accumulation of fluid in the peritoneal cavity, resulting in ascites. The direct leakage of fluid is an after-effect of cancer that spreads to the peritoneum. In addition, there are other illnesses that cause excessive accumulation of water and sodium in the body, which eventually leads to leakage of fluid into the peritoneal cavity.
The other causes of ascites include liver disease, the inability of the organs to produce enough protein to retain fluid in the bloodstream and the obstruction to flow through the scarred cirrhotic liver. The proteins prevent the leakage of water molecules from capillary blood vessels into surrounding tissues. The liver’s ability to produce proteins is decreased by the progression of liver disease, resulting in a lack of protein in the body. Water leaks into the surrounding tissues, thus decreasing oncotic pressure. The common symptoms of ascites are abdominal distension, shortness of breath, shifting dullness, and fluid wave. Monotherapy is considered the most efficient approach for the treatment of ascites where a single drug is used to treat the particular disorder.
According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for ascites. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Want a bigger picture? Try a FREE sample of this report now!
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of ascites. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are
The intravenous route of administration (ROA) involves the direct delivery of liquid substances into the vein and in the intraperitoneal technique, the drug molecules are injected directly into the peritoneum or body cavity, which will have a more direct effect on the target cells.
According to this pipeline analysis report, all the molecules that are currently in the drug pipeline for ascites are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
PART 13: APPENDIX
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.